Physician profile
Jeff Jones
NPI 1669483616
$4,186.88
in general payments reported to CMS, 2019-2025
38 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $283 · 2021: $569 · 2022: $304 · 2023: $325 · 2024: $235 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $867 · Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $867.10 |
| Food and Beverage | $820.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $867.10 | 2025 | |
| Electronic Waveform Lab, INC. | $579.25 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $326.62 | 2019-2022 | |
| Nevro Corp. | $317.96 | 2019-2024 | Senza |
| Boston Scientific Corporation | $228.51 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Tersera Therapeutics LLC | $191.40 | 2019-2020 | |
| Pfizer INC. | $170.54 | 2019-2024 | |
| Scilex Pharmaceuticals INC. | $122.73 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.66 | 2019-2023 | Relistor |
| Biodelivery Sciences International, INC. | $110.05 | 2019-2021 | |
| Medtronic USA, INC. | $105.66 | 2019 | |
| Forte Bio-Pharma LLC | $103.71 | 2020-2022 | |
| Painteq LLC | $102.51 | 2021 | |
| Abbott Laboratories | $99.69 | 2023-2024 | Eterna, Proclaim |
| Medtronic, INC. | $97.25 | 2021-2023 | Intellis Adaptivestim |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $61.08 | 2019 | |
| Redhill Biopharma INC. | $61.07 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Bioventus LLC | $51.88 | 2019-2022 | |
| Janssen Biotech, INC. | $48.76 | 2025 | Tremfya |
| Stimwave Technologies Incorporated | $44.71 | 2019-2021 | |
| Flowonix Medical Incorporated | $40.78 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $36.60 | 2024-2025 | |
| Allergan, INC. | $28.54 | 2019 | |
| Indivior INC. | $26.41 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $23.98 | 2023 | Zilretta, Iovera |
| Mirum Pharmaceuticals, INC. | $22.80 | 2025 | Livmarli |
| Ibsa Pharma INC. | $21.44 | 2021 | |
| Abiomed | $20.83 | 2025 | |
| Assertio Therapeutics, INC. | $20.08 | 2019 | |
| Almatica Pharma LLC | $18.26 | 2021 | |
| Pacira Therapeutics, INC. | $17.99 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.69 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $16.24 | 2022 | |
| Vertos Medical, INC. | $15.59 | 2023 | Mild Device Kit |
| Fidia Pharma USA INC. | $15.18 | 2022 | |
| Horizon Therapeutics Plc | $15.06 | 2020 | |
| Piramal Critical Care | $13.44 | 2022 | |
| Orthogenrx INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.